Talquetamab Dose Modifications May Lower AEs While Maintaini

Dose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma.

Related Keywords

San Francisco , California , United States , Talquetamab Talvey , Helen Diller Family Comprehensive Cancer Center , Myeloma Program , University Of California , Ajai Chari , Multiple Myeloma Program , Diller Family Comprehensive Cancer , Talquetamab , Gprc5d Cd3 Bispecific Antibody , Phase 1 2 Monumental Studies , Relapsed Refractory Multiple Myeloma , 2023 Ash Annual Meeting , Adverse Effects ,